Corvus Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Corvus Pharmaceuticals, Inc.

Jun-09	Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China CRVS GlobeNewswire
May-20	Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference CRVS +6.00% CRVS +7.30% GlobeNewswire
May-14	Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting CRVS -13.79% GlobeNewswire
May-07	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results CRVS -5.57% CRVS +6.58% GlobeNewswire
Apr-23	Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors CRVS -10.25% GlobeNewswire
Apr-21	Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting CRVS +10.30% GlobeNewswire
Mar-12	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results CRVS -5.27% GlobeNewswire
Mar-05	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 CRVS -9.98% GlobeNewswire
Feb-23	Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference CRVS GlobeNewswire
Jan-23	Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M CRVS CRVS -8.33% GlobeNewswire
Jan-21	Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock CRVS +15.21% GlobeNewswire
Jan-20	Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants CRVS +165.96% GlobeNewswire
Jan-20	Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS +165.96% GlobeNewswire
Jan-16	Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS +12.75% GlobeNewswire
Jan-05	Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference CRVS -7.24% GlobeNewswire
Dec-08	Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial CRVS GlobeNewswire
Nov-04	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results CRVS GlobeNewswire
Nov-03	Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition CRVS GlobeNewswire
Oct-31	Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference CRVS GlobeNewswire
Oct-28	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 CRVS GlobeNewswire
Oct-17	Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 CRVS -7.97% GlobeNewswire
Oct-02	Corvus Pharmaceuticals Appoints David Moore to Board of Directors CRVS GlobeNewswire
Aug-07	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results CRVS GlobeNewswire
Jul-31	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 CRVS GlobeNewswire
Jun-25	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis CRVS -5.07% GlobeNewswire
Jun-11	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress CRVS +5.88% GlobeNewswire
Jun-04	Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS -8.98% GlobeNewswire
May-28	Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference CRVS GlobeNewswire
May-08	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results CRVS CRVS +32.24% GlobeNewswire
May-08	Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS CRVS +32.24% GlobeNewswire

Corvus Pharmaceuticals, Inc.

Recent Articles by Corvus Pharmaceuticals, Inc.

Upgrade your Finviz experience